Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort

Cécile Gaujoux-Viala1 Simon Paternotte2 Bernard Combe3 and Maxime Dougados2

首页> 外文期刊>Rheumatology >Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort

【24h】

Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort

机译：甲氨蝶呤作为次类风湿关节炎的首个疾病缓解药物，尽管使用效果欠佳，但其日常症状和结构功效的证据：ESPOIR早期滑膜炎队列研究的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective. To describe the use of MTX in early arthritis (EA) in daily clinical practice and to evaluate its 6-month symptomatic efficacy and 12-month structural efficacy.

机译：目的。在日常临床实践中描述MTX在早期关节炎（EA）中的使用，并评估其6个月的症状功效和12个月的结构功效。

著录项

来源
《Rheumatology》 |2012年第9期|p.1648-1654|共7页
作者
Cécile Gaujoux-Viala1 Simon Paternotte2 Bernard Combe3 and Maxime Dougados2;
展开▼
作者单位

1Pierre and Marie Curie University, Paris 6, AP-HP, Pitié-Salpêtrière Hospital, Department of Rheumatology, Paris, 2Paris 5, Descartes University, AP-HP, Cochin Hospital, Rheumatology B Department, Paris and 3Montpellier University, Lapeyronie Hospital, Department of Rheumatology, Montpellier, France.;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
专利

1. Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: Results from the ESPOIR early synovitis cohort [J] . Gaujoux-VialaC., PaternotteS., CombeB., Rheumatology . 2012,第9期

机译：甲氨蝶呤作为非最佳使用方法在类风湿关节炎中作为第一种疾病改良药物的症状和结构功效的日常证据：ESPOIR早期滑膜炎队列的结果
2. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort [J] . Shimizu Yoko, Tanaka Eiichi, Inoue Eisuke, Modern rheumatology . 2018,第3期

机译：在基于IORRA队列的日常实践中引入类风湿性关节炎患者后，在生物疾病改性抗风湿药物后使用甲氨蝶呤和糖皮质激素的减少
3. Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice [J] . Clinical rheumatology . 2020,第5期

机译：Tocilizumab作为单药治疗或与突尼斯患者中甲氨蝶呤组合的安全性和有效性，具有活跃的类风湿性关节炎，在接近临床实践的条件下对疾病改性抗风湿药物的反应不足
4. The Efficacy of Therapeutic Drug Monitoring of Rheumatoid Arthritis Patients on Infliximab [D] . Abolhosn, Rania. 2018

机译：类风湿性关节炎患者治疗药物监测对英夫利昔单抗的疗效
5. Two-Year Safety and Efficacy Experience in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis Treated with Etanercept and Conventional Disease-Modifying Anti-rheumatic Drugs in the Latin American Region [O] . Daniel A. Machado, Renato Guzman, Ricardo M. Xavier, 2016

机译：拉丁美洲地区使用依那西普和传统抗风湿药治疗甲氨蝶呤耐药的类风湿性关节炎患者的两年安全性和有效性经验
6. Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort [O] . C. Gaujoux-Viala, S. Paternotte, B. Combe, 2012

机译：甲氨蝶呤在日常练习中甲氨蝶呤和结构疗效的证据表明是类风湿性关节炎中的第一个疾病调制药物，尽管其次优不用使用：ESPOIR早期滑膜炎的结果

Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort

摘要

著录项

相似文献

相关主题

期刊订阅